Genmab has filed a patent for a method to treat diffuse large B-cell lymphoma (DLBCL) in human subjects using a bispecific antibody in combination with R-CHOP regimen. The treatment involves specific dosages and administration schedules for each component. GlobalData’s report on Genmab gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Genmab AS - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genmab, Personalized cancer vaccines was a key innovation area identified from patents. Genmab's grant share as of January 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of diffuse large b-cell lymphoma using bispecific antibody

Source: United States Patent and Trademark Office (USPTO). Credit: Genmab AS

A recently filed patent (Publication Number: US20240034812A1) outlines a method for treating diffuse large B-cell lymphoma (DLBCL) in human subjects. The method involves administering a combination of epcoritamab or a biosimilar thereof, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in 21-day cycles. Epcoritamab is administered subcutaneously at varying doses throughout the cycles, while the other components are administered intravenously or orally as specified. The method includes specific dosing schedules and administration frequencies for each component to effectively treat DLBCL.

Furthermore, the patent claims cover various scenarios involving the administration of epcoritamab or its biosimilar at different doses and schedules, in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. The method is tailored for treating DLBCL, including double-hit or triple-hit DLBCL, and follicular lymphoma Grade 3B in subjects with specific prognostic scores. The patent also includes provisions for administering biosimilars of epcoritamab with specific amino acid sequences. Overall, the patent details a comprehensive treatment approach for DLBCL using a specific combination of drugs and dosing regimens to improve patient outcomes.

To know more about GlobalData’s detailed insights on Genmab, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies